Key Drivers
- Margin Expansion
- Strong Cash Flow
- Rising Leverage
AIAI Summary
AMPH's valuation now hinges less on its cash-generative generics base and more on proof that BAQSIMI can overcome 340B/pricing and supply challenges while pipeline and manufacturing execution hold, making confirmation of revenue and margin improvement essential before chasing shares near $24 resistance.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Cash Flow
- •Rising Leverage
AMPH offers improving margins, strong cash flow, and more reasonable valuation, but investors should monitor rising leverage, weaker liquidity, and high intangible-asset exposure.
Price Behavior
Key Price Behavior Insights:
- •Higher price trend
- •Resistance pullback
- •Key support watch
AMPH is moderately bullish over the last month, but watch $23.00 support and $24.00 resistance after its recent pullback.
Three-session retreat from $23.95 to $23.62 signals short-term exhaustion
Sentiment & News
Key News Insights:
- •Sector Tailwinds
- •Pricing Pressure
- •Investor Presentation
Amphastar benefits from improving generic-drug sector trends and will engage investors at the Wells Fargo Healthcare Conference, with no material company-specific catalyst announced.
The update is neutral for Amphastar, signaling industry support and investor visibility but no immediate operational or financial catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings